Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Medicinal and Antitumor Mushroom, Agaricus Blazei Murill, Activates NF-κB Via TLR2 but Not TLR4 In Monocytic Cells, and Stimulates Monocyte-Derived Dendritic Cells (MDDC) to Increased Cell Surface Marker Expression and Cytokine Production, and May Thus Have Adjuvant Effect In MDDC Cancer Vaccines

Geir Hetland, Anne Merete Aaland Tryggestad, Terje Espevik, Liv Ryan, Jon-Magnus Tangen, MD, Egil Johnson, Gunnar Kvalheim

Blood (2010) 116 (21): 3904.

https://doi.org/10.1182/blood.V116.21.3904.3904

Published: 2010

Journal Articles

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Anna Porwit, Peter Hokland, Eva Hellström-Lindberg

Blood (2008) 112 (11): 223.

https://doi.org/10.1182/blood.V112.11.223.223

Published: 2008

Journal Articles

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Peter Hokland, Anna Porwit, Eva Hellström-Lindberg

Blood (2007) 110 (11): 818.

https://doi.org/10.1182/blood.V110.11.818.818

Published: 2007

Journal Articles

Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.

Ulf-Henrik Mellqvist, MD, PhD, Stig Lenhoff, MD, PhD, Martin Hjorth, MD, PhD, Erik Holmberg, PhD, Gunnar Juliusson, MD, PhD, Jon Magnus Tangen, MD, PhD, Jan Westin, MD, PhD, Hans Johnsen, MD, PhD

Blood (2006) 108 (11): 793.

https://doi.org/10.1182/blood.V108.11.793.793

Published: 2006

Journal Articles

Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).

Stig Lenhoff, MD, Martin Hjorth, MD, Peter Gimsing, MD, Jon Magnus Tangen, MD, Jan Westin, MD

Blood (2004) 104 (11): 924.

https://doi.org/10.1182/blood.V104.11.924.924

Published: 2004

Journal Articles

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Eva Hellström-Lindberg, Tomas Ahlgren, Yves Beguin, Magnus Carlsson, Jan Carneskog, Inger Marie Dahl, Ingunn Dybedal, Gunnar Grimfors, Lena Kanter-Lewensohn, Olle Linder, Michaela Luthman, Eva Löfvenberg, Herman Nilsson-Ehle, Jan Samuelsson, Jon-Magnus Tangen, Ingemar Winqvist, Gunnar Öberg, Anders Österborg, Åke Öst

Blood (1998) 92 (1): 68–75.

https://doi.org/10.1182/blood.V92.1.68.413k23_68_75

Published: 1998

NARROW

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.

Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Email alerts

ASH Publications

American Society of Hematology

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.

Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only